Best Peptides for Cardiovascular & Heart Health: Evidence (2026)

Elamipretide is the clear evidence leader and the only peptide in this category with genuine, randomized, placebo-controlled human cardiac trials — plus an FDA approval, though a narrow one. It is a mitochondria-targeting tetrapeptide that binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae and electron-transport-chain supercomplexes, reducing reactive-oxygen-species leak, and preserving ATP — the most mechanistically elegant cardiac peptide story, and also the one most repeatedly humbled by trials. A 2017 double-blind ascending-dose study found that a single four-hour infusion produced a significant, dose-correlated fall in left-ventricular end-diastolic and end-systolic volumes in HFrEF patients, with no change in heart rate or blood pressure. But that acute signal did not survive chronic testing: the follow-up PROGRESS-HF Phase 2 trial in 71 HFrEF patients found no significant change in LV end-systolic volume by cardiac MRI over 28 days. It also did not reduce infarct size in the EMBRACE-STEMI acute-MI trial, and a January 2026 HFpEF rat model improved mitochondrial respiration without improving diastolic function or reversing fibrosis. Its lone approval, as Forzinity in September 2025, is for Barth syndrome — an ultra-rare mitochondrial cardioskeletal disease — not common heart disease. It grades B, not A, because its human RCTs exist but their primary endpoints were negative.

Best for

Cautious scientific interest in mitochondrial cardiac biology — not treating common heart disease

Pricing

Prescription for Barth only; research chemical otherwise — not a sourcing recommendation

Source: Daubert et al., Circ Heart Fail 2017 (PMID 29217757)

No peptide is more intrinsically cardiovascular than angiotensin-(1-7): it is literally a renin-angiotensin-system hormone, the endogenous effector of the protective ACE2/Ang-(1-7)/Mas arm that opposes the classical vasoconstrictor, pro-fibrotic ACE/angiotensin-II/AT1 axis. It triggers endothelial nitric-oxide release, suppresses NADPH-oxidase and NF-κB inflammation, and inhibits TGF-β1/Smad fibrosis across animal models of atherosclerosis, cardiac and renal fibrosis, and cardiomyopathy. It also has more total human-trial experience, including RCTs, than most peptides here. But its human record contains no positive cardiovascular outcome. Its largest, best-powered test — the NIH ACTIV-4 Host Tissue RCT across 35 US sites in hospitalized COVID-19 patients — was clearly negative, with oxygen-free days no different and 28-day mortality essentially identical to placebo; a smaller ICU RCT and a pilot were also non-significant. Its dedicated cardiac program, a Phase 2 in Duchenne-associated cardiomyopathy, has no results yet. The safety signal that matters most is thrombotic: grade-3 DVT at therapeutic doses and vasculitic multifocal strokes at supratherapeutic dose — an antiangiogenic class effect acutely relevant in the vascular-risk, often-anticoagulated population that would want it. It ranks second on mechanistic legitimacy and real trials, but grades C for cardiovascular efficacy because it is proven mainly to be safe, not to work.

Best for

Following a mechanistically legitimate RAS peptide through clinical trials — not for use outside one

Pricing

Research chemical / not FDA-approved — not a sourcing recommendation

Source: Self et al., JAMA 2023 — ACTIV-4 RCTs (PMC10091180)

Thymosin β4 is the repair peptide with the most legitimate cardiac development program — and it never produced a human efficacy result. Its regenerative case rests on a landmark 2004 Nature-lineage finding that thymosin β4 sequesters G-actin to drive cell migration, activates the ILK/PINCH/Akt survival pathway in cardiomyocytes, and reactivates adult epicardial progenitors toward a cardiomyocyte fate in mice, plus rodent post-infarct improvement. In humans, the intravenous form (RGN-352) cleared Phase 1 with safety and tolerability up to 1,260 mg and no dose-limiting toxicity. But the pivotal Phase 2 post-MI/STEMI trial (NCT01311518), planned for roughly 75 patients receiving 450 mg or 1,200 mg IV after PCI, was placed on FDA clinical hold in March 2011 for cGMP manufacturing non-compliance — not a safety or efficacy concern — and was never completed. So no human cardiac efficacy data exist. The heart-regeneration story is real science, but its human evidence stops at Phase 1 safety, making it Grade C, and the marketed claim that thymosin β4 heals your heart badly outruns the data. The principal theoretical concern is pro-angiogenic, pro-migratory activity and tumor-promotion risk, unproven in humans but the most-cited red flag. Critically, this is the full 43-residue protein — not the shorter TB-500 fragment that borrows its reputation.

Best for

Understanding the science of cardiac regeneration — not a proven post-infarct therapy

Pricing

Research chemical / not FDA-approved — not a sourcing recommendation

Source: ClinicalTrials.gov NCT01311518 — RGN-352 (Phase 2, not completed)

TB-500 is the heavily marketed recovery peptide that borrows full-length thymosin β4's reputation while having no human cardiac trial of its own. This is the critical distinction: TB-500 is only the seven-residue actin-binding fragment (Ac-LKKTETQ) of thymosin β4, whereas the human cardiac program used the full 43-residue protein (RGN-352). All credible human thymosin data belong to the full-length protein — and chiefly to topical ophthalmic use — not to the systemic-injection heptapeptide sold as TB-500. For the fragment there is no human evidence at all. Its cardiac case is the same Bock-Marquette ILK/PINCH/Akt mouse work plus a porcine-MI and iPSC-cardiomyocyte study — animal only. There is no validated human protocol; grey-market community use reports roughly 2 to 2.5 mg subcutaneously twice weekly loading then weekly maintenance, extrapolated rather than trial-derived. There is no controlled human safety data, and the theoretical pro-angiogenic, pro-metastatic concern carries over from thymosin β4 tumor-biology studies, layered on top of the product-quality hazard of an unregulated research chemical. It grades C at best where its case rests on preclinical fragment biology, drifting to D where human cardiac use rests on anecdote. Do not transfer the already-modest thymosin β4 evidence to it.

Best for

Illustrating how a fragment borrows a parent peptide's reputation — not for proof

Pricing

Research chemical / not FDA-approved — not a sourcing recommendation

Source: superpower.com — TB-500 vs full-length Tβ4 distinction (2026)

BPC-157 has the broadest preclinical cardiac portfolio of any peptide here — and almost all of it comes from one research group, with zero human cardiovascular trials. A 2022 review reports BPC-157 counteracting isoprenaline-induced myocardial infarction, congestive and doxorubicin-induced heart failure, monocrotaline pulmonary hypertension (normalizing QT prolongation and QRS-axis deviation), diverse arrhythmias (hyper- and hypokalemic, calcium-chloride, digitalis), and thrombosis — all via nitric-oxide-system and Src-Caveolin-1-eNOS modulation, in rats. The breadth is striking, but a 2025 systematic review found that of 36 eligible BPC-157 studies, 35 were preclinical animal experiments and only one involved humans, and independent replication of the cardiac findings is largely absent. For cardiovascular indications there is no human evidence: overall human BPC-157 data are limited to a couple of small safety and pilot reports, including a two-patient IV pilot with no cardiac biomarker changes — not efficacy, not cardiac outcomes. Rodent cardiac studies used microgram-to-nanogram intraperitoneal or intragastric doses; no validated human cardiac dose exists and human pharmacokinetics are unestablished. The nitric-oxide and angiogenic mechanism is double-edged in a vascular population, and product purity is unregulated. It grades C for the single-lab preclinical work, with human cardiac claims at Grade D — intriguing rodent breadth, no human cardiac evidence, and a replication gap.

Best for

Following an intriguing but unreplicated preclinical cardiac hypothesis — not for treatment

Pricing

Research chemical / not FDA-approved — not a sourcing recommendation

Source: Sikiric et al., Biomedicines 2022 (PMID 36359218)